Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials

World Journal of Gastroenterology

Volumn 13, Issue 17, 2007, Pages 2496-2503

  Cheng, Die ^a,b   Xu, Wei Ren ^b   Liu, Chang Xiao ^b  

^a TIANJIN UNIVERSITY   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

Elimination half life; Fluoroquinolones; Genetic function approximation; Quantitative structure pharmacokinetic relationship

Indexed keywords

AMIFLOXACIN; ANTIBIOTIC AGENT; BALOFLOXACIN; CIPROFLOXACIN; CLINAFLOXACIN; DIFLOXACIN; ENOXACIN; FANDOFLOXACIN; FLEROXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RUFLOXACIN; SITAFLOXACIN; SPARFLOXACIN; TEMAFLOXACIN; TOSUFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; COMPUTER PROGRAM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; HUMAN; MATHEMATICAL MODEL; MEDICAL LITERATURE; POLARIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 34250617466     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i17.2496     Document Type: Article

References (69)

1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272: 65-69
2. Leung WK, Hung LC, Kwok CK, Leong RW, Ng DK, Sung JJ. Follow up of serial urea breath test results in patients after consumption of antibiotics for non-gastric infections. World J Gastroenterol 2002; 8: 703-706
3. Ibrahim M, Khan AA, Tiwari SK, Habeeb MA, Khaja MN, Habibullah CM. Antimicrobial activity of Sapindus mukorossi and Rheum emodi extracts against H pylori: In vitro and in vivo studies. World J Gastroenterol 2006; 12: 7136-7142
4. Klopman G, Fercu D, Renau TE, Jacobs MR. N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies. Antimicrob Agents Chemother 1996; 40: 2637-2643
5. Norris DA, Leesman GD, Sinko PJ, Grass GM. Development of predictive pharmacokinetic simulation models for drug discovery. J Control Release 2000; 65: 55-62
6. Ghafourian T, Fooladi S. The effect of structural QSAR parameters on skin penetration. Int J Pharm 2001; 217: 1-11
7. Feher M, Sourial E, Schmidt JM. A simple model for the prediction of blood-brain partitioning. Int J Pharm 2000; 201: 239-247
8. Wajima T, Fukumura K, Yano Y, Oguma T. Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: oral clearance. J Pharm Sci 2003; 92: 2427-2440
9. Cook JA, Silverman MH, Schelling DJ, Nix DE, Schentag JJ, Brown RR, Stroshane RM. Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. Antimicrob Agents Chemother 1990; 34: 974-979
10. Stroshane RM, Silverman MH, Sauerschell R, Brown RR, Boddy AW, Cook JA. Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects. Antimicrob Agents Chemother 1990; 34: 751-754
11. Kozawa O, Uematsu T, Matsuno H, Niwa M, Nagashima S, Kanamaru M. Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects. Antimicrob Agents Chemother 1996; 40: 2824-2828
12. Lubasch A, Keller I, Berner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600-2603
13. Boy D, Well M, Kinzig-Schippers M, Sorgel F, Ankel-Fuchs D, Naber KG. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int J Antimicrob Agents 2004; 23 Suppl 1: S6-S16
14. Zhang J, Zhang YY, Shi YG, Yu JC, Wang L. Clinical pharmacokinetics study on ciprofloxacin. Zhongguo Yaolixue Tongbao 1996; 12: 430-433
15. Xiao YH, Wang QN, Qian YS, Du JZ, Zheng XP, Liu HY. Pharmacokinetics and in vitro antibacterial activity of ciprofloxacin. Zhongguo Kangshengsu Zazhi 1992; 17: 293-296
16. Randinitis EJ, Koup JR, Rausch G, Abel R, Bron NJ, Hounslow NJ, Vassos AB, Sedman AI. Clinafloxacin pharmacokinetics in subjects with various degrees of renal function. Antimicrob Agents Chemother 2001; 45: 2536-2542
17. Randinitis EJ, Brodfuehrer JI, Eiseman I, Vassos AB. Pharmacokinetics of clinafloxacin after single and multiple doses. Antmicrob Agents Chemother 2001; 45: 2529-2535
18. Wise R, Jones S, Das I, Andrews JM. Pharmacokinetics and inflammatory fluid penetration of clinafloxacin. Antimicrob Agents Chemother 1998; 42: 428-430
19. Meyerhoff C, Dilger C, Yoon SJ, Chung YH, Lee DK, Lee CW, Ryu JM, Choi MS, Pabst G, Reh C. Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. J Antimicrob Chemother 1998; 42: 349-361
20. Qian YS, Wang QN, Xiao YH, Du JZ, Zheng XP, Li CZ, Liu HY, Qiu J, Jiang FY. Pharmacokinetics study of enoxacin in human and in vitro antibactial activity. Zhongguo Kangshengsu Zazhi 1992; 17: 215-218
21. Zeng JZ, Liang DR, Qin YP, Liang MZ, Liu DY, Huang Y, Zhang HM, Yu Q, Zou YG., Zhang HL. Study on the pharmacokinetics of oral enoxacin and bioavailabilities of preparations in healthy volunteers. Zhongguo Kangshengsu Zazhi 1993; 18: 341-346
22. Xiao YH, Wang QN, Qian YS, Du JZ, He HX. Pharmacokinetics of enoxacin, ciprofloxacin, ofloxacin and pefloxacin. Chongqing Yikedaxue Xuebao 1994; 19: 177-179
23. Trampuz A, Laifer G, Wenk M, Rajacic Z, Zimmerli W. Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate. Antimicrob Agents Chemother 2002; 46: 3630-3633
24. Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother 1999; 43: 1067-1071
25. Liu XD, Xie L, Wang J, Liang Y, Li L, Lu L. Comparison of pharmacokinetics of gatifloxacin in rats, dogs and humans. Asian J drug Metab Pharmacokinet 2005; 5: 71-76
26. Wise R, Andrews JM, Ashby JP, Marshall J. A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J Antimicrob Chemother 1999; 44: 701-704
27. Allen A, Bygate E, Oliver S, Johnson M, Ward C, Cheon AJ, Choo YS, Kim IC. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob Agents Chemother 2000; 44: 1604-1608
28. Gee T, Andrews JM, Ashby JP, Marshall G, Wise R. Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. J Antimicrob Chemother 2001; 47: 431-434
29. Allen A, Bygate E, Vousden M, Oliver S, Johnson M, Ward C, Cheon A, Choo YS, Kim I. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. Antimicrob Agents Chemother 2001; 45: 540-545
30. Child J, Andrews JM, Wise R. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrob Agents Chemother 1995; 39: 513-515
31. Efthymiopoulos C. Pharmacokinetics of grepafloxacin. J Antimicrob Chemother 1997; 40 Suppl A: 35-43
32. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600-2603
33. Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, Williams RR, Fowler CL, Cheung WK, Chow AT. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997; 41: 2256-2260
34. Chien SC, Chow AT, Natarajan J, Williams RR, Wong FA, Rogge MC, Nayak RK. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997; 41: 1562-1565
35. Stone JW, Andrews JM, Ashby JP, Griggs D, Wise R. Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother 1988; 32: 1508-1510
36. Kovarik JM, Hoepelman AI, Smit JM, Sips PA, Rozenberg-Arska M, Glerum JH, Verhoef J. Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. Antimicrob Agents Chemother 1992; 36: 2458-2461
37. Tan L, Xu DK, Diao Y, Yuan YS. Highperformance liquid chromatographic assay for lomefloxacin in plasma and its pharmacokinetics in healthy volunteers. Yaoxue Xuebao 1993; 28: 286-289
38. Tang X, Cai YM. Effects of probenicid on the pharmacokinetics of norfloxacin. Shenyang Yaoxueyuan Xuebao 1991; 8: 1-4
39. Adhami ZN, Wise R, Weston D, Crump B. The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother 1984; 13: 87-92
40. Lehto P, Kivisto KT. Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob Agents Chemother 1994; 38: 248-251
41. Yuk JH, Nightingale CH, Quintiliani R, Sweeney KR. Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob Agents Chemother 1991; 35: 384-386
42. Immanuel C, Hemanthkumar AK, Gurumurthy P, Venkatesan P. Dose related pharmacokinetics of ofloxacin in healthy volunteers. Int J Tuberc Lung Dis 2002; 6: 1017-1022
43. Hameed A, Iqbal T, Nawaz M, Batool F, Baig TT, Ali S, Nurjis F. Pharmacokinetics of ofloxacin in male volunteers following oral administration. Pak J Biol Sci 2002; 5: 1098-1100
44. Israel D, Gillum JG, Turik M, Harvey K, Ford J, Dalton H, Towle M, Echols R, Heller AH, Polk R. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1993; 37: 2193-2199
45. Lode H, Hoffken G, Olschewski P, Sievers B, Kirch A, Borner K, Koeppe P. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antitnicrob Agents Chemother 1987; 31: 1338-1342
46. De Lepeleire I, Van Hecken A, Verbesselt R, Tjandra-Maga TB, De Schepper PJ. Comparative oral pharmacokinetics of fleroxacin and pefloxacin. J Antimicrob Chemother 1988; 22: 197-202
47. Wang WL, Lu H, Wang T, Hou F, Li JT. Pharmacokinetics of pefloxacin in normal volunteers. Zhongguo Linchuang Yaolixue Zazhi 1990; 6: 235-241
48. Xiao YH, Wang QN, Qian YS, Du JZ, Zheng XP, Liu HY. Pharmacokinetics and in vitro antibacterial activity of pefloxacin. Zhongguo Kangshengsu Zazhi 1992; 17: 302-305
49. Imbimbo BP, Broccali G, Cesana M, Crema F, Attardo-Parrinello G. Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers. Antimicrob Agents Chemother 1991; 35: 390-393
50. Wise R, Johnson J, O'Sullivan N, Andrews JM, Imbimbo BP. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent. J Antimicrob Chemother 1991; 28: 905-909
51. Perry G, Mant TG, Morrison PJ, Sacks S, Woodcock J, Wise R, Imbimbo BP. Pharmacokinetics of rufloxacin in patients with impaired renal function. Antimicrob Agents Chemother 1993; 37: 637-641
52. Kisicki JC, Griess RS, Ott CL, Cohen GM, McCormack RJ, Troetel WM, Imbimbo BP. Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers. Antimicrob Agents Chemother 1992; 36: 1296-1301
53. O'Grady J, Briggs A, Atarashi S, Kobayashi H, Smith RL, Ward J, Ward C, Milatovic D. Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluotoquinolone antibiotic, in healthy male and female Caucasian subjects. Xenobiotica 2001; 31: 811-822
54. Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Tanaka M. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1995; 39: 170-174
55. Johnson JH, Cooper MA, Andrews JM, Wise R. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother 1992; 36: 2444-2446
56. Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H. Pharmacokinetics of sparfloxacin and interaction with cisapricle and sucralfate. Antimicrob Agents Chemother 1997, 41: 1668-1672
57. Mody VD, Pandya KK, Satia MC, Modi IA, Modi RI, Gandhi TP. High performance thin-layer chromatographic method for the determination of sparfloxacin in human plasma and its use in pharmacokinetic studies. J Pharm Biomed Anal 1998; 16: 1289-1294
58. Matsuoka M, Banno K, Sato T. Analytical chiral separation of a new quinolone compound in biological fluids by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996; 676: 117-124
59. Granneman GR, Carpentier P, Morrison PJ, Pernet AG. Pharmacokinetics of temafloxacin in humans after single oral doses. Antimicrob Agents Chemother 1991; 35: 436-4341
60. Granneman GR, Braeckman R, Kraut J, Shupien S, Craft JC. Temafloxacin pharmacokinetics in subjects with normal and impaired renal function. Antimicrob Agents Chemother 1991; 35: 2345-2351
61. Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother 1996; 37: 955-963
62. Vincent J, Venitz J, Teng R, Baris BA, Willavize SA, Polzer RJ, Friedman HL. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J Antimicrob Chemother 1997, 39 Suppl B: 75-80
63. Wise R, Mortiboy D, Child J, Andrews JM. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother 1996; 40: 47-49
64. Granneman GR, Snyder KM, Shu VS. Difloxacin metabolism and pharmacokinetics in humans after single oral doses. Antimicrob Agents Chemother 1986; 30: 689-693
65. Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060-2065
66. Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 1999; 43 Suppl B: 69-76
67. Minami R, Inotsume N, Nakamura C, Nakano M. Stereoselective analysis of the disposition of tosufloxacin enantiomers in man. Eur J Clin Pharmacol 1993; 45: 489-491
68. Niki Y. Pharmacokinetics and safety assessment of tosufloxacin tosilate. J Infect Chemother 2002; 8: 1-18
69. Minami R, Nakamura C, Inotsume N, Nakano M. Effects of aluminum hydroxide and famotidine on bioavailability of tosufloxacin in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 453-455